Low-grade intestinal inflammation two decades after pelvic radiotherapy

Devarakonda, Sravani; Thorsell, Annika; Hedenstrom, Per; Rezapour, Azar; Heden, Lisen; Banerjee, Sanghita; Johansson, Malin E. V.; Birchenough, George; Moren, Amelie Toft; Gustavsson, Karin; Skokic, Viktor; Pettersson, Victor L.; Sjoberg, Fei; Kalm, Marie; Al Masri, Mohammad; et. al.

Abstract

Background Radiotherapy is effective in the treatment of cancer but also causes damage to non-cancerous tissue. Pelvic radiotherapy may produce chronic and debilitating bowel symptoms, yet the underlying pathophysiology is still undefined. Most notably, although pelvic radiotherapy causes an acute intestinal inflammation there is no consensus on whether the late-phase pathophysiology contains an inflammatory component or not. To address this knowledge gap, we examined the potential presence of a chronic inflammation in mucosal biopsies from irradiated pelvic cancer survivors.Methods We biopsied 24 cancer survivors two to 20 years after pelvic radiotherapy, and four non-irradiated controls. Using tandem mass tag (TMT) mass spectrometry and mRNA sequencing (mRNA-seq), we charted proteomic and transcriptomic profiles of the mucosal tissue previously exposed to a high or a low/no dose of radiation. Changes in the immune cell populations were determined with flow cytometry. The integrity of the protective mucus layers were determined by permeability analysis and 16S rRNA bacterial detection.Findings 942 proteins were differentially expressed in mucosa previously exposed to a high radiation dose compared to a low radiation dose. The data suggested a chronic low-grade inflammation with neutrophil activity, which was confirmed by mRNA-seq and flow cytometry and further supported by findings of a weakened mucus barrier with bacterial infiltration.Interpretation Our results challenge the idea that pelvic radiotherapy causes an acute intestinal inflammation that either heals or turns fibrotic without progression to chronic inflammation. This provides a rationale for exploring novel strategies to mitigate chronic bowel symptoms in pelvic cancer survivors.

Más información

Título según WOS: ID WOS:001047577900001 Not found in local WOS DB
Título de la Revista: EBIOMEDICINE
Volumen: 94
Editorial: Elsevier
Fecha de publicación: 2023
DOI:

10.1016/j.ebiom.2023.104691

Notas: ISI